Harpoon Therapeutics, Inc. (HARP) Tops Q2 EPS by 37c

Harpoon Therapeutics, Inc. (NASDAQ: HARP) reported Q2 EPS of $0.03, $0.37 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $20.22 million versus the consensus estimate of $5.14 million.

For earnings history and earnings-related data on Harpoon Therapeutics, Inc. (HARP) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Vislink Technologies Inc. (VISL) Misses Q2 EPS by 7c
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30